Literature DB >> 1748053

Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM.

C E Mogensen1, K W Hansen, M M Pedersen, C K Christensen.   

Abstract

In this article, we analyze the blood pressure (BP) threshold for the start of antihypertensive treatment in insulin-dependent diabetes mellitus (IDDM) patients, with particular emphasis on those with persistent microalbuminuria or proteinuria (incipient and overt nephropathy, respectively). In such individuals, there is a clear increase in the prevalence of hypertension and in actual measured BP values that is not observed in normoalbuminuric patients. In 94 young healthy adults (less than 45 yr of age), average mean +/- SD arterial pressure (MAP; diastolic + 1/3 pulse pressure) was approximately 90.0 +/- 8.1 mmHg, closely corresponding to large population studies. In microalbuminuric IDDM patients, MAP values between approximately 105 and approximately 95 mmHg have been found in different studies, and the level has progressively decreased in various studies between 1984 and 1990 with similar BP-measuring techniques. Somewhat higher values are seen in patients with proteinuria, who are also consistently characterized by reduced glomerular filtration rate (GFR). A clear correlation is found between MAP plotted against the increased rate of microalbuminuria (%/yr) in incipient nephropathy and against fall rate of GFR (ml.min-1.mo-1) in proteinuric patients. In the natural history of renal disease, different cutoff points in MAP for start of progression are observed: greater than 95 mmHg for the start of progression of microalbuminuria and greater than 105 mmHg for the decrease in GFR. During antihypertensive treatment, there is reduction or no progression in microalbuminuria with MAP of approximately 90-95 mmHg and only a limited fall in GFR with MAP of approximately 100 mmHg. However, certain antihypertensive drugs (angiotensin-converting enzyme inhibitors) may have specific renoprotective actions, reducing microalbuminuria at rather low BP levels or even independent of BP reduction. The optimal way of monitoring BP may be by 24-h ambulatory recording.

Entities:  

Mesh:

Year:  1991        PMID: 1748053     DOI: 10.2337/diacare.14.4.13

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  11 in total

Review 1.  Is it possible to predict diabetic kidney disease?

Authors:  S M Thomas; G C Viberti
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

2.  Angiotensin converting enzyme inhibitors and diabetic nephropathy.

Authors:  C E Mogensen
Journal:  BMJ       Date:  1992-02-08

3.  Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.

Authors:  R D Feldman; N R Campbell; P Larochelle
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

4.  1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

Authors:  R D Feldman; N Campbell; P Larochelle; P Bolli; E D Burgess; S G Carruthers; J S Floras; R B Haynes; G Honos; F H Leenen; L A Leiter; A G Logan; M G Myers; J D Spence; K B Zarnke
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

5.  ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH.

Authors:  Ali A Rizvi
Journal:  Eur Med J Diabetes       Date:  2017-10

Review 6.  Hypertension in diabetes and the risk of cardiovascular disease.

Authors:  Nirmal Sunkara; Chowdhury H Ahsan
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

Review 7.  Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.

Authors:  Jay Garg; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 8.  The diabetic patient with hypertension.

Authors:  G P Leese; M W Savage; P D Chattington; J P Vora
Journal:  Postgrad Med J       Date:  1996-05       Impact factor: 2.401

Review 9.  Combating diabetic nephropathy with drug therapy.

Authors:  D Martins; K Norris
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

10.  Impact of diabetes on cardiovascular disease: an update.

Authors:  Alessandra Saldanha de Mattos Matheus; Lucianne Righeti Monteiro Tannus; Roberta Arnoldi Cobas; Catia C Sousa Palma; Carlos Antonio Negrato; Marilia de Brito Gomes
Journal:  Int J Hypertens       Date:  2013-03-04       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.